The evolution of S100B inhibitors for the treatment of malignant melanoma.

In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction.

S100B is highly over-expressed in many cancers, including malignant melanoma. In such cancers, S100B binds wild-type p53 in a calcium-dependent manner, sequestering it, and promoting its degradation, resulting in the loss of p53-dependent tumor suppression activities. Therefore, S100B inhibitors may be able to restore wild-type p53 levels in certain cancers and provide a useful therapeutic stra...

New therapeutical approaches for the treatment of malignant Melanoma

Malignant Melanoma of the External Auditory Canal:A Rare Entity

Introduction: Although malignant melanomas (MM) are common in the head and neck region; primary malignant melanoma of the external auditory canal (EAC) is rare.   Case Report: We present the case of a 50-year-old symptomatic man with a malignant melanoma of the external auditory canal, which clinically masqueraded as a haemangioma. The patient subsequently developed extensive loco-regional me...

Covalent Small Molecule Inhibitors of Ca2+-Bound S100B

Elevated levels of the tumor marker S100B are observed in malignant melanoma, and this EF-hand-containing protein was shown to directly bind wild-type (wt) p53 in a Ca(2+)-dependent manner, dissociate the p53 tetramer, and inhibit its tumor suppression functions. Likewise, inhibiting S100B with small interfering RNA (siRNA(S100B)) is sufficient to restore wild-type p53 levels and its downstream...

Diagnosis and Management of a Malignant Dermal Melanoma in a Donkey (Equus asinus)

Case Description- A 2-yr-old intact male donkey (Equus asinus) was presented to Hospital of Veterinary Medicine, Mansoura University with subcutaneous masses under the tail. Clinical Findings- Physical examination revealed the presence of 2 separate 5x10 and 5x8-cm-diameter, round and firm subcutaneous masses. Treatment and Outcome<...